vs
CytomX Therapeutics, Inc.（CTMX）与Rent the Runway, Inc.（RENT）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是Rent the Runway, Inc.的1.8倍（$18.7M vs $10.6M），Rent the Runway, Inc.净利率更高（721.7% vs -0.8%，领先722.5%），Rent the Runway, Inc.同比增速更快（10.4% vs -25.7%），过去两年Rent the Runway, Inc.的营收复合增速更高（1.0% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Rent the Runway Inc.是总部位于纽约的美国电商平台，由珍妮弗·海曼与珍妮弗·弗莱斯于2009年11月创立，主打设计师品牌服饰与配饰的租赁、订阅以及购买服务，是设计师服饰共享租赁模式的开创平台之一。
CTMX vs RENT — 直观对比
营收规模更大
CTMX
是对方的1.8倍
$10.6M
营收增速更快
RENT
高出36.1%
-25.7%
净利率更高
RENT
高出722.5%
-0.8%
两年增速更快
RENT
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $10.6M |
| 净利润 | $-154.0K | $76.5M |
| 毛利率 | — | -126.4% |
| 营业利润率 | -6.9% | -152.8% |
| 净利率 | -0.8% | 721.7% |
| 营收同比 | -25.7% | 10.4% |
| 净利润同比 | 97.6% | 504.8% |
| 每股收益（稀释后） | — | $13.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXRENT
| Q4 25 | — | $10.6M | ||
| Q3 25 | — | $11.7M | ||
| Q2 25 | $18.7M | $7.6M | ||
| Q1 25 | $50.9M | $11.8M | ||
| Q4 24 | $38.1M | $9.6M | ||
| Q3 24 | $33.4M | $10.4M | ||
| Q2 24 | $25.1M | $8.9M | ||
| Q1 24 | $41.5M | $10.4M |
净利润CTMXRENT
| Q4 25 | — | $76.5M | ||
| Q3 25 | — | $-26.4M | ||
| Q2 25 | $-154.0K | $-26.1M | ||
| Q1 25 | $23.5M | $-13.4M | ||
| Q4 24 | $18.9M | $-18.9M | ||
| Q3 24 | $5.7M | $-15.6M | ||
| Q2 24 | $-6.5M | $-22.0M | ||
| Q1 24 | $13.8M | $-24.8M |
毛利率CTMXRENT
| Q4 25 | — | -126.4% | ||
| Q3 25 | — | -92.3% | ||
| Q2 25 | — | -168.4% | ||
| Q1 25 | — | -71.2% | ||
| Q4 24 | — | -122.9% | ||
| Q3 24 | — | -98.1% | ||
| Q2 24 | — | -131.5% | ||
| Q1 24 | — | -93.3% |
营业利润率CTMXRENT
| Q4 25 | — | -152.8% | ||
| Q3 25 | — | -171.8% | ||
| Q2 25 | -6.9% | -259.2% | ||
| Q1 25 | 44.4% | -65.3% | ||
| Q4 24 | 46.4% | -142.7% | ||
| Q3 24 | 12.3% | -92.3% | ||
| Q2 24 | -33.7% | -185.4% | ||
| Q1 24 | 28.1% | -185.6% |
净利率CTMXRENT
| Q4 25 | — | 721.7% | ||
| Q3 25 | — | -225.6% | ||
| Q2 25 | -0.8% | -343.4% | ||
| Q1 25 | 46.2% | -113.6% | ||
| Q4 24 | 49.6% | -196.9% | ||
| Q3 24 | 17.2% | -150.0% | ||
| Q2 24 | -26.0% | -247.2% | ||
| Q1 24 | 33.3% | -238.5% |
每股收益（稀释后）CTMXRENT
| Q4 25 | — | $13.65 | ||
| Q3 25 | — | $-6.55 | ||
| Q2 25 | — | $-6.58 | ||
| Q1 25 | — | $-2.72 | ||
| Q4 24 | — | $-4.70 | ||
| Q3 24 | — | $-4.17 | ||
| Q2 24 | — | $-6.03 | ||
| Q1 24 | — | $-5.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $50.7M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $-35.1M |
| 总资产 | $175.1M | $231.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXRENT
| Q4 25 | — | $50.7M | ||
| Q3 25 | — | $43.6M | ||
| Q2 25 | $49.0M | $70.4M | ||
| Q1 25 | $47.6M | $77.4M | ||
| Q4 24 | $38.1M | $74.1M | ||
| Q3 24 | $40.6M | $76.6M | ||
| Q2 24 | $43.2M | $82.0M | ||
| Q1 24 | $36.2M | $84.0M |
总债务CTMXRENT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $340.6M | ||
| Q1 25 | — | $333.7M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益CTMXRENT
| Q4 25 | — | $-35.1M | ||
| Q3 25 | — | $-232.1M | ||
| Q2 25 | $119.9M | $-207.1M | ||
| Q1 25 | $25.0M | $-182.5M | ||
| Q4 24 | $-456.0K | $-171.2M | ||
| Q3 24 | $-23.5M | $-154.5M | ||
| Q2 24 | $-31.2M | $-141.3M | ||
| Q1 24 | $-31.7M | $-122.3M |
总资产CTMXRENT
| Q4 25 | — | $231.0M | ||
| Q3 25 | — | $219.0M | ||
| Q2 25 | $175.1M | $245.3M | ||
| Q1 25 | $98.5M | $240.0M | ||
| Q4 24 | $120.5M | $251.6M | ||
| Q3 24 | $139.0M | $257.4M | ||
| Q2 24 | $159.2M | $278.4M | ||
| Q1 24 | $184.7M | $278.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-1.4M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | — |
| 自由现金流率自由现金流/营收 | -84.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | -0.02× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | — |
8季度趋势，按日历期对齐
经营现金流CTMXRENT
| Q4 25 | — | $-1.4M | ||
| Q3 25 | — | $-10.5M | ||
| Q2 25 | $-15.8M | $8.3M | ||
| Q1 25 | $-21.0M | $1.4M | ||
| Q4 24 | $-19.9M | $4.7M | ||
| Q3 24 | $-20.7M | $2.2M | ||
| Q2 24 | $-19.5M | $4.6M | ||
| Q1 24 | $-26.0M | $-8.0M |
自由现金流CTMXRENT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
自由现金流率CTMXRENT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
资本支出强度CTMXRENT
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
现金转化率CTMXRENT
| Q4 25 | — | -0.02× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RENT
暂无分部数据
